Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma

Evasive mechanisms triggered by the tyrosine kinase inhibitor sorafenib reduce its efficacy in hepatocellular carcinoma (HCC) treatment. Drug-resistant cancer cells frequently exhibit sphingolipid dysregulation, reducing chemotherapeutic cytotoxicity via the induction of ceramide-degrading enzymes....

Descripción completa

Detalles Bibliográficos
Autores principales: Stefanovic, Milica, Tutusaus, Anna, Martinez-Nieto, Guillermo A., Bárcena, Cristina, de Gregorio, Estefania, Moutinho, Catia, Barbero-Camps, Elisabet, Villanueva, Alberto, Colell, Anna, Marí, Montserrat, García-Ruiz, Carmen, Fernandez-Checa, Jose C., Morales, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884990/
https://www.ncbi.nlm.nih.gov/pubmed/26811497
http://dx.doi.org/10.18632/oncotarget.6982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884990/
https://www.ncbi.nlm.nih.gov/pubmed/26811497
http://dx.doi.org/10.18632/oncotarget.6982

Ejemplares similares